 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || BI 905711 / Boehringer Ingelheim
Trial completion, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Jan 18, 2024
P1, N=13, Completed, Sponsor: Boehringer Ingelheim
Terminated --> Completed
- ||| BI 905711 / Boehringer Ingelheim
Trial completion, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Dec 18, 2023
P1, N=110, Completed, Sponsor: Boehringer Ingelheim
Terminated --> Completed Active, not recruiting --> Completed
- ||| BI 905711 / Boehringer Ingelheim
Phase classification, Trial completion date, Trial termination, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Dec 13, 2023
P1, N=13, Terminated, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Phase classification: P1a/1b --> P1 | Trial completion date: Mar 2024 --> Oct 2023 | Active, not recruiting --> Terminated
- || BI 905711 / Boehringer Ingelheim
Trial primary completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Nov 28, 2023
P1, N=110, Active, not recruiting, Sponsor: Boehringer Ingelheim
Phase classification: P1a/1b --> P1 | Trial completion date: Mar 2024 --> Oct 2023 | Active, not recruiting --> Terminated Trial primary completion date: Jan 2024 --> Jul 2023
- | BI 905711 / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Oct 31, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jan 2024 --> Jul 2023 Trial primary completion date: Mar 2024 --> Oct 2023
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Sep 13, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Mar 2024 --> Oct 2023 Trial completion date: Sep 2024 --> Mar 2024
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Sep 11, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Sep 2024 --> Mar 2024 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- || BI 905711 / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Apr 19, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024 N=10 --> 13
- || BI 905711 / Boehringer Ingelheim
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Apr 18, 2023
P1a/1b, N=10, Active, not recruiting, Sponsor: Boehringer Ingelheim
N=10 --> 13 Recruiting --> Active, not recruiting | N=100 --> 10 | Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Jun 2024 --> Sep 2023
- || BI 905711 / Boehringer Ingelheim
Enrollment closed, Trial completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 18, 2023
P1, N=110, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | N=100 --> 10 | Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Jun 2024 --> Sep 2023 Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Sep 2023
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Dec 14, 2022
P1, N=140, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Sep 2023 Trial completion date: Jun 2023 --> Jun 2024
- BI 905711 / Boehringer Ingelheim
A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. (On Demand | Level 1, West Hall; Poster Board No. F12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_779;
P1
BI 905711 will be further assessed in Phase Ib in 4 dose groups: 0.6/1.2/2.4 mg/kg every 14 days, and 0.6 mg/kg weekly. Clinical trial information: NCT04137289.
- BI 905711 / Boehringer Ingelheim
A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. (Available On Demand; Poster Board No. P10) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_373;
P1a/1b
In the PDAC cohort, pts with CDH17+ PDAC with prior progression on gemcitabine-based first-line therapy will receive FOLFIRI + BI 905711...The study is ongoing. Clinical trial information: NCT05087992.
- BI 905711 / Boehringer Ingelheim
A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2029;
P1
Conclusions BI 905711 showed a tolerable safety profile with favourable PK properties. Early signs of disease control in these heavily pretreated pts was observed and will be further assessed in phase Ib in 4 dose groups: 0.6/1.2/2.4 mg/kg every 14 days, and 0.6 mg/kg weekly.
- BI 905711 / Boehringer Ingelheim
A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_290;
P1a/1b
In preclinical models of GI cancer, including colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), BI 905711 showed activity both as a single agent and in combination with chemotherapeutic agents (Garcia-Martinez et al., Mol Cancer Ther 2021; 20:96–108). Preclinical studies also showed synergism of BI 905711 and SoC chemotherapy, particularly irinotecan.
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 4, 2022
P1, N=140, Recruiting, Sponsor: Boehringer Ingelheim
Preclinical studies also showed synergism of BI 905711 and SoC chemotherapy, particularly irinotecan. Trial completion date: Mar 2023 --> Jun 2023
- BI 905711 / Boehringer Ingelheim
A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_613;
P1
Secondary endpoints include PK parameters and OR in pts with measurable disease (phase Ia), and disease control, tumor shrinkage, duration of response, and progression-free survival (phase Ib). Trial enrollment is ongoing, with 33 pts enrolled to date.
- ||| BI 905711 / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Dec 2, 2021
P1a/1b, N=100, Recruiting, Sponsor: Boehringer Ingelheim
Trial enrollment is ongoing, with 33 pts enrolled to date. Not yet recruiting --> Recruiting
- ||| BI 905711 / Boehringer Ingelheim
New P1 trial, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Oct 20, 2021
P1a/1b, N=100, Not yet recruiting, Sponsor: Boehringer Ingelheim
- | irinotecan / Generic mfg.
Preclinical, Journal: Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist. (Pubmed Central) - Aug 14, 2021
P1
In summary, we demonstrate that BI 905711 has potent and selective antitumor activity in CDH17-positive colorectal cancer models both in vitro and in vivo. The high prevalence of over 95 percent CDH17-positive tumors in CRC patients, the molecule preclinical efficacy together with its potential for a favorable safety profile, support the ongoing BI 905711 phase I trial in CRC and additional CDH17-positive cancer types (NCT04137289).
- ||| BI 905711 / Boehringer Ingelheim
Yes, an actual novel target: Uni of Penn licenses anti-CDH17 Car to Chimeric Therapeutics https://t.co/ZYlRbSnJlF Boehringer has BI 905711, TRAILR2 x CDH17 bispecific MAb, in ph1 (Twitter) - Jul 28, 2021
- BI 905711 / Boehringer Ingelheim
[VIRTUAL] BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models () - Mar 13, 2021 - Abstract #AACR2021AACR_4355;
P1
Responders to BI 905711 were identified primarily within the classical and quasi-basal/hybrid subtypes when TRAILR2 was adequately co-expressed. This correlates with an enrichment pattern of CDH17 gene expression that is mostly within the classical gene cluster and strongly anti-correlated with basal-like cluster enrichment.Robust preclinical anti-tumor activity of BI 905711 in TRAILR2 and CDH17-expressing PDAC PDX models, along with this antibody’s potential for a favorable safety profile, has justified the enrollment of pancreatic cancer patients in the ongoing BI 905711 FIH Phase I clinical trial (NCT04137289).
- ||||| BI 905711 / Boehringer Ingelheim
Preclinical: BI 905711, a bispecific antibody targeting TRAILR2 and CDH17, has potent and selective #AntitumorActivity in CDH17-positive #ColorectalCancer models both in vitro and in vivo. Paper by Garcia-Martinez. @Boehringer @JM_GaMar @norbertkraut1 https://t.co/TsUeOOASi8 (Twitter) - Feb 3, 2021
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Jul 7, 2020
P1, N=140, Recruiting, Sponsor: Boehringer Ingelheim
This correlates with an enrichment pattern of CDH17 gene expression that is mostly within the classical gene cluster and strongly anti-correlated with basal-like cluster enrichment.Robust preclinical anti-tumor activity of BI 905711 in TRAILR2 and CDH17-expressing PDAC PDX models, along with this antibody’s potential for a favorable safety profile, has justified the enrollment of pancreatic cancer patients in the ongoing BI 905711 FIH Phase I clinical trial (NCT04137289). Trial completion date: Apr 2024 --> May 2023
- ||| BI 905711 / Boehringer Ingelheim
Enrollment open, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 26, 2020
P1, N=140, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Apr 2024 --> May 2023 Suspended --> Recruiting
- BI 905711 / Boehringer Ingelheim
[VIRTUAL] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_317;
P1
Legal entity responsible for the study The authors. Funding Boehringer Ingelheim.
- |||| BI 905711 / Boehringer Ingelheim
Trial suspension, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 6, 2020
P1, N=140, Suspended, Sponsor: Boehringer Ingelheim
Funding Boehringer Ingelheim. Not yet recruiting --> Suspended
- BI 905677 / Boehringer Ingelheim, BI 905711 / Boehringer Ingelheim, BI 1701963 / Boehringer Ingelheim
[VIRTUAL] Expanding the Druggable Cancer Target Space (Room 16 A-B - Mezz Lvl - SDCC) - Mar 6, 2020 - Abstract #AACR2020AACR_775;
BI 1701963 is the first SOS1::KRAS inhibitor to advance to clinical trials and, in combination with RAS/MAPK pathway-targeted drugs, represents an approach to target a broad spectrum of mutant KRAS-driven cancers, including major non-G12C-mutated cancers...BI 905677 is a first-in-class LRP5/6 antagonist in phase 1 studies that effectively targets WNT-driven proliferation and immune escape...BI 905711 is scheduled to enter phase 1 clinical trials in early 2020. Collectively, these three areas of precision medicines promise to significantly expand the druggable target space and offer much-needed therapeutic options to cancer patients.
- || BI 905711 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Jan 7, 2020
P1, N=140, Not yet recruiting, Sponsor: Boehringer Ingelheim
Collectively, these three areas of precision medicines promise to significantly expand the druggable target space and offer much-needed therapeutic options to cancer patients. Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Nov 2022 --> Apr 2023
- ||| BI 905711 / Boehringer Ingelheim
New P1 trial, Metastases: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Oct 28, 2019
P1, N=140, Not yet recruiting, Sponsor: Boehringer Ingelheim